UNSPSC 51422207: Flunarizine dihydrochloride

This classification denotes a calcium channel blocker with the molecular formula C26H26F2N2.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C11102TO53, chemically known as piperazine, 1-(bis(p-fluorophenyl)methyl)-4-cinnamyl-, dihydrochloride, (e)- but more generally known as flunarizine dihydrochloride, which bears US NIH Compound Identifier 5282407. European Medicines Agency schedules Flunarizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02213MIG.

Most nations, for tariff and trade purposes, schedule flunarizine dihydrochloride under HS 29335995 and SITC 51576. SMILES: C1CCC(CC1)/C=C/CN2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F.CL.CL.

UNSPSC 51422207 Flunarizine dihydrochloride is a Commodity code that captures pharmaceutical products procured by state and local health agencies, though recent state and local solicitations tagged to this code show minimal alignment with the specific pharmaceutical named in the code itself. Seminole County, Florida posted an IFB in June 2026 for naloxone and drug deactivation systems—opioid-response medications and harm-reduction equipment—rather than flunarizine, a calcium-channel blocker used for migraine prevention. The Texas Health and Human Services Commission issued an RFI in April 2026 exploring direct-to-manufacturer prescription fulfillment models that would apply broadly across pharmaceutical categories, including but not limited to specialty therapeutics, without naming flunarizine or any specific active ingredient. The issuing bodies reflect state health departments and county public-health operations seeking to manage pharmacy benefits, control costs, and support community health initiatives through competitive procurement.

Geographic activity centers on Florida and Texas based on the recent opportunities. Seminole County's naloxone procurement targets quarterly deliveries to a community health building in Sanford, Florida, with an IFB response deadline of July 26, 2023 (note: the posting date of June 30, 2026 and the due date of July 26, 2023 reflect inconsistencies in the source record). The Texas HHS Commission's RFI, posted April 3, 2026 with the same response date, signals early-stage exploration of direct pharmaceutical contracting that would serve state employee and retiree health plans statewide. The code shows limited recent activity specifically tied to flunarizine procurement; opportunities present under the code involve broader pharmaceutical procurement mechanisms and opioid-response products rather than the migraine medication nominally identified by the UNSPSC number.